Archived AES Symposia 2008
Annual Course: Matching Treatments to Seizures and Syndromes
Program Length: 6 hrs 6 min
Innovations in care for patients with epilepsy evolve rapidly. Thus, it is impossible for the busy clinician to keep abreast of all the new treatments and their place in the therapy of epilepsy without getting a periodic comprehensive update. This course is designed to provide clinicians who treat epilepsy with the newest information about management of seizures and epilepsy syndromes. Discussion will focus on the numerous new therapies now available, including medications, diets, and surgical procedures and stimulators. The aim of this course is to offer information so that the clinicians will be able to logically choose and offer the best therapy available for each epilepsy patient.
- Increase the frequency with which you suspect a diagnosis of Dravet syndrome in patients with refractory seizures coupled with certain phenotypic signs
- Have increased knowledge of and confidence in your ability to prescribe newer therapies for seizure reduction in patients with Dravet syndrome
- Identify and evaluate the pros and cons associated with treating and not treating benign epilepsy of childhood with rolandic spikes
- Avoid delay in offering advanced therapies to patients with atonic or tonic seizures that have proven refractory to frontline therapy
- Select therapy for absence seizures that offers the best chance at seizure reduction and the least chance for seizure aggravation, based on the best available evidence
- Select pharmacotherapy for JME in women of childbearing age that has the lowest risk for poor outcomes in future pregnancies, based on the best available evidence
- Have increased confidence in your ability to select the best AED therapy for patients with partial onset seizures.
- Select pharmacotherapy for patients with refractory seizures that offer the best chance at seizure reduction, based on the best available evidence.
Neurologists, epileptologists, nurse specialists, pharmacists and other healthcare professionals
Co-Chairs: Elinor Ben-Menachem, M.D., Ph.D. and Michael Sperling, M.D.
Introduction and Opening Remarks
Elinor Ben-Menachem, M.D., Ph.D.
Etiology and Diagnosis Even in the Adult Population: How to Find Patients and Treatment Suggestions
Alexis A. Arzimanoglu, M.D.
Debate: To Treat or Not to Treat and If So, With What?
W. Donald Shields, M.D. and O. Carter Snead III, M.D.
Medical Therapy and Ketogenic Diet
Eileen P. G. Vining, M.D.
Debate: What’s Next? VNS vs. Callosotomy?
David W. Roberts, M.D. and William E. Rosenfeld, M.D.
Treatment Causes of Seizure Aggravation in Idiopathic Epilepsies, Especially Absences
Ernest Somerville, FRACP
Debate: Use a New AED or an Old One (VPA or ETH) as First Drug for Treatment of Absence?
L. James Willmore, M.D. and Patricia E. Penovich, M.D.
Debate: In a Girl, What Is the First Line Therapy? Use Valproate First vs. Use a New AED First – Which One?
Georgia D. Montouris, M.D. and Bassel W. Abou-Khalil, M.D.
Tailoring Initial Drug Therapy to Individual Patient Needs in Partial Onset Seizures
R. Eugene Ramsay, M.D.
Debate: Should Enzyme Inducing Drugs Be Considered as First Line Agents?
Richard H. Mattson, M.D. and Scott Mintzer, M.D.
Treatment Algorithms for Treating Refractory Partial Epilepsy
Barbara C. Jobst, M.D.
Debate: Is There a Significant Advantage to Be Gained by Trying Additional AEDs After Two Have Failed or Go Directly to Early Surgery Evaluation?
Patrick Kwan, M.D. and Michael Sperling, M.D.
Debate: Rational Polytherapy: Is There Such a Thing?
Jacqueline A. French, M.D. and R. Edward Faught, Jr., M.D.
Surgical Treatment of Extratemporal Epilepsy
William E. Bingaman, M.D.
Michael Sperling, M.D.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.